Formulation Patent definition
Examples of Formulation Patent in a sentence
Appendix B2 sets forth an accurate and complete list of all Ipsen Formulation Patent Rights on the Effective Date.
There are no other patents licensed to ATL pursuant to the ISIS Agreement, including without limitation, the ISIS Formulation Patent Rights, Research Target Patent Rights or any other ISIS Patent Rights (as such terms are defined in the ISIS Agreement) that are necessary or useful to Exploit the Technology in the Field in the Territory for the Purpose.
In no event shall more than one such royalty be due Unigene hereunder with respect to the sale of each Licensed Product, even if such Licensed Product is covered by more than one Valid Claim within the Unigene Formulation Patent Rights.
In the event Section 3.4.3 does not apply, where Substantial Similar Competition by a Similar Product exists in a country in which a Licensed Product covered by a Valid Claim of Unigene Formulation Patent Rights is being sold, the applicable royalties set forth in Section 3.4.1 on Net Sales in such country shall be reduced by *** percent (***%) for each Calendar Quarter in which Substantial Similar Competition exists.
In the event that no royalty on certain Net Sales is paid under Section 3.4 because the Licensed Product for sale is not covered by a Valid Claim of Unigene Formulation Patent Rights, then as further consideration for the licenses granted to GSK under Section 2.1 of this Agreement, GSK shall pay to Unigene *** percent (***%) of the otherwise applicable royalty rate set forth in Section 3.4.1 on such Net Sales.
Where Substantial Equivalent Competition by an Equivalent Product exists in a country in which a Licensed Product covered by a Valid Claim of Unigene Formulation Patent Rights is being sold, the applicable royalties set forth in Section 3.4.1 on Net Sales in such country shall be reduced by *** percent (***%) for each Calendar Quarter in which Substantial Equivalent Competition exists.
Such amounts are due and payable for the term of issued and unexpired claims within the ISIS Formulation Patent Rights.
Where substantial competition by an Equivalent Product exists in a country in which a Valid Claim within all Unigene Formulation Patent Rights exists, the applicable royalties set forth in Section 3.4.1 on Net Sales in such country shall be reduced by ** percent (**%) for each Calendar Quarter in which substantial competition exists.
Additionally, in case of such supply by OMP a royalty of [***] on Net Sales shall be paid by Grünenthal until the last to expire of any OMP-ADF- Formulation Patent which claims the Product.
The obligation of GSK to pay royalties under Section 3.4 shall continue for each Licensed Product on a Licensed Product-by-Licensed Product and country-by-country basis, until such time as there are no Valid Claims of Unigene Formulation Patent Rights covering the manufacture, sale or use of such Licensed Product in such country.